OBJECTIVES This study sought to describe the impact of statins on individual coronary atherosclerotic plaques.BACKGROUND Although statins reduce the risk of major adverse cardiovascular events, their long-term effects on coronary atherosclerosis remain unclear.METHODS We performed a prospective, multinational study consisting of a registry of consecutive patients without history of coronary artery disease who underwent serial coronary computed tomography angiography at an interscan interval of >= 2years. Atherosclerotic plaques were quantitatively analyzed for percent diameter stenosis (%DS), percent atheroma volume (PAV), plaque composition, and presence of high-risk plaque (HRP), defined by the presence of >= 2 features of low-attenuation plaque, positive arterial remodeling, or spotty calcifications.RESULTS Among 1,255 patients (60 +/- 9 years of age; 57% men), 1,079 coronary artery lesions were evaluated in statin-naive patients (n = 474), and 2,496 coronary artery Lesions were evaluated in statin-taking patients (n = 781). Compared with Lesions in statin-naive patients, those in statin-taking patients displayed a slower rate of overall PAV progression (1.76 +/- 2.40% per year vs. 2.04 +/- 2.37% per year, respectively; p = 0.002) but more rapid progression of calcified PAV (1.27 +/- 1.54% per year vs. 0.98 +/- 1.27% per year, respectively; p < 0.001). Progression of noncalcified PAV and annual incidence of new HRP features were lower in Lesions in statin-taking patients (0.49 +/- 2.39% per year vs. 1.06 +/- 2.42% per year and 0.9% per year vs. 1.6% per year, respectively; all p < 0.001). The rates of progression to >50% DS were not different (1.0% vs. 1.4%, respectively; p > 0.05). Statins were associated with a 21% reduction in annualized total PAV progression above the median and 35% reduction in HRP development.CONCLUSIONS Statins were associated with slower progression of overall coronary atherosclerosis volume, with increased plaque calcification and reduction of high-risk plaque features. Statins did not affect the progression of percentage of stenosis severity of coronary artery lesions but induced phenotypic plaque transformation. (C) 2018 by the American College of Cardiology Foundation.

Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study / S. Lee, H. Chang, J.M. Sung, H. Park, R. Heo, A. Rizvi, F.Y. Lin, A. Kumar, M. Hadamitzky, Y.J. Kim, E. Conte, D. Andreini, G. Pontone, M.J. Budoff, I. Gottlieb, B.K. Lee, E.J. Chun, F. Cademartiri, E. Maffei, H. Marques, J.A. Leipsic, S. Shin, J.H. Choi, K. Chinnaiyan, G. Raff, R. Virmani, H. Samady, P.H. Stone, D.S. Berman, J. Narula, L.J. Shaw, J.J. Bax, J.K. Min. - In: JACC: CARDIOVASCULAR IMAGING. - ISSN 1876-7591. - 11:10(2018 Oct), pp. 1475-1484. [10.1016/j.jcmg.2018.04.015]

Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study

E. Conte;D. Andreini;G. Pontone;
2018

Abstract

OBJECTIVES This study sought to describe the impact of statins on individual coronary atherosclerotic plaques.BACKGROUND Although statins reduce the risk of major adverse cardiovascular events, their long-term effects on coronary atherosclerosis remain unclear.METHODS We performed a prospective, multinational study consisting of a registry of consecutive patients without history of coronary artery disease who underwent serial coronary computed tomography angiography at an interscan interval of >= 2years. Atherosclerotic plaques were quantitatively analyzed for percent diameter stenosis (%DS), percent atheroma volume (PAV), plaque composition, and presence of high-risk plaque (HRP), defined by the presence of >= 2 features of low-attenuation plaque, positive arterial remodeling, or spotty calcifications.RESULTS Among 1,255 patients (60 +/- 9 years of age; 57% men), 1,079 coronary artery lesions were evaluated in statin-naive patients (n = 474), and 2,496 coronary artery Lesions were evaluated in statin-taking patients (n = 781). Compared with Lesions in statin-naive patients, those in statin-taking patients displayed a slower rate of overall PAV progression (1.76 +/- 2.40% per year vs. 2.04 +/- 2.37% per year, respectively; p = 0.002) but more rapid progression of calcified PAV (1.27 +/- 1.54% per year vs. 0.98 +/- 1.27% per year, respectively; p < 0.001). Progression of noncalcified PAV and annual incidence of new HRP features were lower in Lesions in statin-taking patients (0.49 +/- 2.39% per year vs. 1.06 +/- 2.42% per year and 0.9% per year vs. 1.6% per year, respectively; all p < 0.001). The rates of progression to >50% DS were not different (1.0% vs. 1.4%, respectively; p > 0.05). Statins were associated with a 21% reduction in annualized total PAV progression above the median and 35% reduction in HRP development.CONCLUSIONS Statins were associated with slower progression of overall coronary atherosclerosis volume, with increased plaque calcification and reduction of high-risk plaque features. Statins did not affect the progression of percentage of stenosis severity of coronary artery lesions but induced phenotypic plaque transformation. (C) 2018 by the American College of Cardiology Foundation.
coronary artery atherosclerosis; coronary artery disease; coronary computed tomography angiography; statins
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
ott-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
effects.pdf

accesso riservato

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 739.31 kB
Formato Adobe PDF
739.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/956209
Citazioni
  • ???jsp.display-item.citation.pmc??? 78
  • Scopus 344
  • ???jsp.display-item.citation.isi??? 318
social impact